ADVERTISEMENTs
.png)
Rep. Jayapal among 90 Democrats condemning Trump’s NIH cuts
They warned that funding uncertainty could drive young scientists to leave the field or seek opportunities abroad, undermining U.S. leadership in medical research.
Pramila Jayapal / Image- secular.org
Indian American Representative Pramila Jayapal has joined 90 House Democrats in condemning the Trump administration’s funding cuts to the National Institutes of Health (NIH), warning that they threaten critical medical research, including clinical trials for Alzheimer’s and cancer treatments.
Jayapal, in a social media post, stating, “Trump and Elon are slashing funding for scientists working on cures to Alzheimer’s and cancer. Funding that would save lives. Restore NIH funding NOW,” she wrote.
ICYMI: I joined 90 House Democrats in denouncing Trump’s cuts to NIH and demanding answers on the threats they pose.
— Rep. Pramila Jayapal (@RepJayapal) February 10, 2025
Trump and Elon are slashing funding for scientists working on cures to Alzheimer’s and cancer. Funding that would save lives.
Restore NIH funding NOW. pic.twitter.com/HCFyAbtAGv
In a letter addressed to acting NIH director Matthew J. Memoli, the lawmakers demanded immediate action to reinstate funding and resume essential clinical trials. They raised concerns over reports of researchers at the NIH’s clinical trial center struggling to procure necessary supplies, such as test tubes for blood draws, due to disrupted purchasing orders.
“We demand that you take immediate action to resume this public-facing work, which has broad ramifications that affect everyday Americans,” the letter stated. The lawmakers also highlighted the suspension of review panels for major Alzheimer’s clinical trials, warning that delays in research grant approvals could slow the development of new treatments.
The letter further warned that funding uncertainty could drive young scientists to leave the field or seek opportunities abroad, undermining U.S. leadership in medical research. “This is a time when we want to attract the best talent and not lose it to China, Germany, or Canada,” the lawmakers wrote.
Additionally, the signatories expressed concern over the removal of guidance documents related to clinical trial diversity, urging their reinstatement to ensure studies accurately represent diverse patient populations.
“The NIH is mission critical,” the letter concluded. “Every day that no new studies are being launched, no pre printing, no procurement or contracting for new studies, equipment or research means one less cure or clinical trial that could save someone’s life.”
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
.jpg)
Video
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login